

# TABLE OF CONTENTS

March 9, 2009

No. 2130

## BUSINESS

- 1 Eisai to Create Independent Units in 6 Fields to Accelerate Development  
- Aiming at Global Simultaneous Applications for 2 Compounds  
- Eisai Licenses Adhesive Aricept from Teikoku Seiyaku
- 3 Daiichi Sankyo Pursues Optimal Promotion Mixes  
- e-Detailing Effective for CV Drugs
- 4 Teva-Kowa Aims at Becoming a Leading GE Maker in Japan in 2015
- 4 Shire Enters Japanese Market by Opening Office in Tokyo
- 5 Abbott Japan Acquires Rights to Market Amitiza in Japan
- 5 **BUSINESS NEWS IN BRIEF**  
- Kyorin Licenses Uritos to Saudi Arabian Company  
- Takeda Starts Promoting KAPIDEX in US  
- Maruho Takes Over Astat from Tsumura  
- Daiichi Sankyo to Reshuffle Organization on April 1  
- Shionogi Creates Sugar Chain Analysis Contract Lab in US  
- Bristol-Myers Recalls Kenacort-A

## TOPICS

- Drugs Detected in Water from Tap Water Sources

## REGULATORY

- 8 11 APIs Recommended for Approval  
- Sales of Over ¥10 Bil. Expected for 4 APIs  
- Lucentis, Xolair to Be Reimbursed Based on Piecework Principle
- 8 Cell Cultured Vaccine for Japanese Encephalitis from BIKEN Approved  
- Recommended for Use in Periodic Vaccination Programs
- 11 Prasugrel Approved in EU
- 11 GSK's Tykerb Recommended for Approval
- 12 2 Combinations of ARB and Diuretic to Become Available Soon
- 12 Data from Ranbaxy Plant Are Falsified: FDA  
- Stability Data Falsified
- 13 **REGULATORY NEWS IN BRIEF**  
- Increased Dose of Amlodipine Approved

## R&D

- 13 Clinical Trial Operations Streamlined at Pfizer Japan  
- Paying Fees Based on Actual Number of Subjects Enrolled  
- Using EDC in All Trials  
- Number of Development Team Members Reduced from 17 to 6

- 14 Astellas to Diversify Development Programs
- 15 **R&D NEWS IN BRIEF**  
- PMDA Calls For More Collaborative Multinational Trials  
- Nippon Kayaku Starts Additional Trial for Hycamtin  
- Sanofi Pasteur Starts PII Study of *C. Difficile* Vaccine  
- Pfizer Drops 2 PIII Compounds  
- Sandostatin LAR Reduces NETs Tumors Growth: Novartis  
- Zometa Data on Risk of Breast Cancer Recurrence Published in NEJM: Novartis

## MEDICAL DEVICES

- 16 RDKK Maintains Higher-Than-Industry-Average Growth Rate
- 17 Review Period Reduced, but Submittal Lag Still Long: ACCJ Report  
- High Regulatory Costs Are Major Problem  
- Proposals to Eliminate Submission Lag and Reduce Review Time

## SELF-MEDICATION

- 18 Council Starts Deliberating Online Sale of OTC Drugs  
- Majority of Members against Online Sale  
- JODA Considers Suing *Koroshō*  
- *Koroshō* Should Publish All Public Comments Received: Mr Goto
- 19 Fewer OTC Drug Wholesalers Report Profits despite Increases in Sales: FJPWA Survey
- 20 2nd OTC Drug Wholesaler with Nationwide Coverage to Be Created

## GENERICIS

- 20 NCVC Announces List of Generics Adopted by It
- 20 Pharmacists' Cooperation Essential to Increase Use of Generics

## MEDICAL FACILITIES & NURSING CARE

- 21 Sanjou General Hospital Causes Stir by Switching Back to In-house Prescriptions
- 21 Opposition Disagrees with Reappointment of Prof. Maeda as *Chuikyo* Member  
- New Rule Is Necessary: Mr Masuzoe  
- *Chuikyo* Members Question Disapproval by Opposition  
- Group of Patients, Victims of Medical Accidents also Support Prof. Maeda
- 22 Tasigna Recommended in 2nd-Line Therapy: Prof. Ohyashiki
- 23 Chugai's Avastin Should Be Indicated for Stomach Cancer
- 23 Constipation Should Be Treated by Physicians: Dr Hongo